AstraZeneca COPD drug cuts exacerbations in two Phase 3 trials

AstraZeneca reported that its investigational COPD treatment significantly reduced exacerbations in two late-stage trials, a positive efficacy signal for a major respiratory indication. The data, while not yet fully detailed, could support regulatory filings and reshape the COPD treatment landscape. Market impact is likely sector-specific, with potential upside for AstraZeneca shares.